IF 1.8

Pharmacy Pub Date : 2025-07-21 DOI: 10.3390/pharmacy13040097

Yuyao Pei, Ruoxin Huang, Feng Chang, Yuanhui Hu, Sarah Versteeg, Yufen Zheng

{"title":"The Role of Pharmacists in Delivering Pharmaceutical Services to Breast Cancer Patients in Clinical and Community Settings: A Scoping Review.","authors":"Yuyao Pei, Ruoxin Huang, Feng Chang, Yuanhui Hu, Sarah Versteeg, Yufen Zheng","doi":"10.3390/pharmacy13040097","DOIUrl":"10.3390/pharmacy13040097","url":null,"abstract":"(1) Background: Patient-centered care for individuals with breast cancer requires multidisciplinary cooperation to ensure the appropriate use of medication and prevent medication-related problems. Pharmaceutical care has been associated with improved adherence in breast cancer management, a factor linked to patient outcomes and mortality. This study aims to summarize and explore the provision and utilization of pharmaceutical services for breast cancer patients by pharmacists. (2) Methods: A scoping review was performed to assess the pharmacist's role in providing pharmaceutical services for patients with breast cancer. A comprehensive review of four databases (PubMed, Ovid Embase, Ovid International Pharmaceutical Abstracts, and Scopus) was completed between 1 January 2012 and 8 April 2025 according to PRISMA-ScR framework. (3) Results: A total of 46 articles met the inclusion criteria, which included RCTs, observatory studies, cohort studies, and reviews. Findings suggest that both clinical and community pharmacists play an important role in prevention, management, and education for breast cancer patients. (4) Conclusions: Pharmacists can improve health outcomes by providing pharmaceutical service in breast cancer care. Optimizing interventions, expanding services, and evaluating long-term cost-effectiveness is needed in the future.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials. 麦角酸酰胺（LSA），一种LSD类似物：药理作用、不良后果和治疗潜力的系统综述。

IF 1.8

Pharmacy Pub Date : 2025-07-21 DOI: 10.3390/pharmacy13040098

Paula S C C Castro, Kae Leopoldo, Maria Olivia Pozzolo Pedro, Juliana Takitane, Henrique Silva Bombana, André Brooking Negrão, Jaqueline R Scholz, João Maurício Castaldelli-Maia

{"title":"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials.","authors":"Paula S C C Castro, Kae Leopoldo, Maria Olivia Pozzolo Pedro, Juliana Takitane, Henrique Silva Bombana, André Brooking Negrão, Jaqueline R Scholz, João Maurício Castaldelli-Maia","doi":"10.3390/pharmacy13040098","DOIUrl":"10.3390/pharmacy13040098","url":null,"abstract":"Objective: To systematically review the scientific literature on lysergic acid amide (LSA), focusing on its physical, neurobiological, and social effects, as well as its potential risks and therapeutic uses. Methods: A systematic review was conducted across PubMed, Google Scholar, and Web of Science up to December 2023, using keywords such as \"ergine,\" \"lysergic acid amide,\" and \"legal high.\" Studies were included if they reported original human data on the physical, neurobiological, psychological, or social effects of LSA; seventeen studies were included. Animal studies, in vitro research, and non-original articles were excluded. Two independent reviewers screened and selected the studies, with a third resolving discrepancies. Data were extracted using a standardized form. The review followed PRISMA guidelines and was prospectively registered on the Open Science Framework. Results: LSA is primarily consumed through preparations made from the seeds of Convolvulaceae plants. Reported effects include euphoria, hallucinations, nausea, and anxiety. Severe adverse outcomes, such as psychosis, hypertension, and hospitalization, have also been documented. Some evidence suggests its potential therapeutic application for cluster headaches. However, variability in dosing and misinformation on digital platforms heighten the risks associated with LSA use. Conclusions: LSA poses significant health risks, exacerbated by online misinformation and variability in its effects, and a lack of scientific studies. Further research is essential to clarify its pharmacological profile, establish guidelines for safe use, and raise public awareness about its dangers.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medical Cannabis Use and Healthcare Utilization Among Patients with Chronic Pain: A Causal Inference Analysis Using TMLE. 慢性疼痛患者的医用大麻使用与医疗保健利用：基于TMLE的因果推理分析

IF 1.8

Pharmacy Pub Date : 2025-07-15 DOI: 10.3390/pharmacy13040096

Mitchell L Doucette, Emily Fisher, Junella Chin, Panagiota Kitsantas

{"title":"Medical Cannabis Use and Healthcare Utilization Among Patients with Chronic Pain: A Causal Inference Analysis Using TMLE.","authors":"Mitchell L Doucette, Emily Fisher, Junella Chin, Panagiota Kitsantas","doi":"10.3390/pharmacy13040096","DOIUrl":"10.3390/pharmacy13040096","url":null,"abstract":"Introduction: Chronic pain affects approximately 20% of U.S. adults, imposing significant burdens on individuals and healthcare systems. Medical cannabis has emerged as a potential therapy, yet its impact on healthcare utilization remains unclear.Methods: This retrospective cohort study analyzed administrative data from a telehealth platform providing medical cannabis certifications across 36 U.S. states. Patients were classified as cannabis-exposed if they had used cannabis in the past year, while unexposed patients had no prior cannabis use. Outcomes included self-reported urgent care visits, emergency department (ED) visits, hospitalizations, and quality of life (QoL), measured using the CDC's Healthy Days measure. Targeted Maximum Likelihood Estimation with SuperLearner estimated causal effects, adjusting for numerous covariates.Results: Medical cannabis users exhibited significantly lower healthcare utilization. Specifically, exposure was associated with a 2.0 percentage point reduction in urgent care visits (95% CI: -0.036, -0.004), a 3.2 percentage point reduction in ED visits (95% CI: -0.051, -0.012) and fewer unhealthy days per month (-3.52 days, 95% CI: -4.28, -2.76). Hospitalization rates trended lower but were not statistically significant. Covariate balance and propensity score overlap indicated well-fitting models.Conclusions: Medical cannabis use was associated with reduced healthcare utilization and improved self-reported QoL among chronic pain patients.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Pharmacists in Identifying and Preventing Drug-Related Problems in PCOS Management. 药师在多囊卵巢综合征管理中识别和预防药物相关问题中的作用。

IF 1.8

Pharmacy Pub Date : 2025-07-11 DOI: 10.3390/pharmacy13040095

Hristina Lebanova, Vesselina Yanachkova, Svetoslav Stoev

{"title":"The Role of Pharmacists in Identifying and Preventing Drug-Related Problems in PCOS Management.","authors":"Hristina Lebanova, Vesselina Yanachkova, Svetoslav Stoev","doi":"10.3390/pharmacy13040095","DOIUrl":"10.3390/pharmacy13040095","url":null,"abstract":"Polycystic ovary syndrome (PCOS) is an endocrine disorder prevalent in women of reproductive age, often requiring complex pharmacological management. The heterogeneity of the syndrome and the use of on- and off-label therapeutic agents-ranging from insulin sensitizers and ovulation inducers to oral contraceptives and herbal supplements-pose significant challenges, including adverse effects, drug interactions, and poor adherence. This narrative review explores the role of pharmacists in identifying and mitigating drug-related problems (DRPs) associated with PCOS therapy. Through thematic synthesis of the current literature, the study highlights common DRPs such as suboptimal drug selection, inappropriate dosing, prolonged therapy duration, and treatment-related safety concerns. It underscores the value of pharmacists' interventions in enhancing medication adherence, optimizing therapeutic regimens, providing patient education, and monitoring adverse events. A structured, patient-level pharmaceutical care model is proposed, emphasizing personalized assessment, interdisciplinary collaboration, and continuous follow-up. The integration of clinical pharmacists into PCOS care teams has the potential to improve treatment effectiveness, patient satisfaction, and long-term health outcomes. Pharmacists' contributions are especially critical given the widespread use of off-label therapies and supplements with variable evidence of benefit. Tailored pharmaceutical care can thus bridge the existing gaps in PCOS management and enhance the quality of life for the affected individuals.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing the Role of Community Pharmacists in Medication Safety: A Qualitative Study of Voices from the Frontline. 加强社区药师在用药安全中的作用：来自一线声音的定性研究。

IF 1.8

Pharmacy Pub Date : 2025-07-09 DOI: 10.3390/pharmacy13040094

Annesha White, Erika L Thompson, Solyi Kim, Janice A Osei, Kimberly G Fulda, Yan Xiao

{"title":"Enhancing the Role of Community Pharmacists in Medication Safety: A Qualitative Study of Voices from the Frontline.","authors":"Annesha White, Erika L Thompson, Solyi Kim, Janice A Osei, Kimberly G Fulda, Yan Xiao","doi":"10.3390/pharmacy13040094","DOIUrl":"10.3390/pharmacy13040094","url":null,"abstract":"Preventable adverse drug events (ADEs) remain a significant threat in community settings, a challenge that is critical in community pharmacy settings where continuity of care and healthcare access can be limited. This qualitative study explored the perspectives of 13 community pharmacists through focus groups and interviews to identify barriers and propose solutions to enhance their role in patient care. Pharmacists emphasized their critical position in ensuring safe medication use, particularly for older adults managing multiple chronic conditions. Key findings revealed five themes: (1) defining medication safety as minimizing risk and empowering patients; (2) characteristics of the \"perfect patient,\" including medication awareness and proactive engagement; (3) the pharmacist's role in detecting and resolving medication-related problems; (4) systemic barriers such as time constraints, lack of access to patient records, insufficient privacy, and undervaluation of pharmacists' roles; and (5) proposed solutions including private counseling areas, increased staffing, integrated electronic health records, and legislative recognition of pharmacists as healthcare providers. Strengthening collaboration with physicians and empowering patients through education were also highlighted as key strategies. These findings underscore the need for systemic changes-especially in light of lessons learned during the pandemic-to support pharmacists in delivering comprehensive medication management and improving patient safety.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type II Diabetes Mellitus and COVID-19: Exploring Insulin Management in Patients from Family Medicine Clinics. 2型糖尿病与COVID-19：家庭医学门诊患者胰岛素管理的探讨

IF 1.8

Pharmacy Pub Date : 2025-07-04 DOI: 10.3390/pharmacy13040093

Chinemerem Opara, Annesha White, Kimberly G Fulda, Somer Blair, Clare Aduwari, Nihitha Nukala, Yan Xiao

{"title":"Type II Diabetes Mellitus and COVID-19: Exploring Insulin Management in Patients from Family Medicine Clinics.","authors":"Chinemerem Opara, Annesha White, Kimberly G Fulda, Somer Blair, Clare Aduwari, Nihitha Nukala, Yan Xiao","doi":"10.3390/pharmacy13040093","DOIUrl":"10.3390/pharmacy13040093","url":null,"abstract":"The COVID-19 pandemic disrupted routine care for individuals with type 2 diabetes mellitus (T2DM), raising concerns about its impact on glycemic control and medication management. This study evaluated the relationship between insulin use and glycemic control among T2DM patients during the pandemic. A retrospective analysis was conducted using deidentified clinical and prescription data from two family medicine clinics, comparing data from the pre-COVID-19 period (1 March 2019-13 March 2020) and during the COVID-19 pandemic (14 March 2020-31 March 2021). Patients included had at least two A1c values before the COVID and one during the COVID. A1c control was defined as less than 8%. Among 992 patients, 238 experienced a change in A1c status: 128 improved and 110 worsened. Mean A1c remained stable at 8.2 across both periods. A majority of patients who improved were using insulin during the COVID-19 era, although some discontinued insulin at some point during the study period. These findings suggest that consistent insulin therapy may have helped maintain glycemic control despite healthcare disruptions. This study highlights the importance of sustained medication management and suggests that integrating telehealth and pharmacist-led care could support diabetes control during future healthcare system challenges.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polysubstance Use and Social Sequelae in Women of Reproductive Age with Recent Marijuana Use. 近期使用大麻的育龄妇女的多物质使用和社会后遗症。

IF 1.8

Pharmacy Pub Date : 2025-07-02 DOI: 10.3390/pharmacy13040092

Sean Hyungwoo Kim, Hua Min, Hong Xue, Panagiota Kitsantas

{"title":"Polysubstance Use and Social Sequelae in Women of Reproductive Age with Recent Marijuana Use.","authors":"Sean Hyungwoo Kim, Hua Min, Hong Xue, Panagiota Kitsantas","doi":"10.3390/pharmacy13040092","DOIUrl":"10.3390/pharmacy13040092","url":null,"abstract":"Polysubstance use (PSU) involving marijuana among women of reproductive age (WRA) is linked to psychosocial harm, yet research on the combined effects of marijuana with stimulants, opioids, tobacco, and binge drinking remains limited. The purpose of this study was to assess the prevalence of PSU in WRA with past month MJ use and examine the association between PSU status and social sequelae, including getting in trouble with the law, relationship difficulty with others, and lower achievement in job or educational settings, in this group of women. We used data from the United States 2015-2019 National Survey on Drug Use and Health, which included 11,895 non-institutionalized WRA (18-44 years old) with reported use of MJ in the past month. Descriptive statistics, chi-squared tests, and multivariable logistic regression analyses were conducted to describe the sample and assess associations between PSU and social sequelae. Nearly 4.5% of the women who used MJ in the past month had experienced social sequelae regardless of PSU status. Women who used three or more substances along with MJ had the highest adjusted odds (AOR = 3.18, 95% CI 1.90, 5.31) of social sequelae relative to monosubstance MJ users. Concurrent use of multiple substances significantly increased the likelihood of social sequelae among women MJ users.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Visual Thinking to Explore "Relational Pharmacology": Systemic Maps for Managing Non-Selective Antidepressants in Cardiovascular Prevention. 探索“关系药理学”的视觉思维：管理心血管预防非选择性抗抑郁药的系统地图。

IF 1.8

Pharmacy Pub Date : 2025-06-27 DOI: 10.3390/pharmacy13040091

Irene García-Domínguez, Azahara Rodríguez-Luna, Manuel Machuca

{"title":"Visual Thinking to Explore \"Relational Pharmacology\": Systemic Maps for Managing Non-Selective Antidepressants in Cardiovascular Prevention.","authors":"Irene García-Domínguez, Azahara Rodríguez-Luna, Manuel Machuca","doi":"10.3390/pharmacy13040091","DOIUrl":"10.3390/pharmacy13040091","url":null,"abstract":"Relational pharmacology introduces an innovative approach using visual thinking to understand how drugs interact with multiple body systems, addressing the limitations of the traditional \"reductionist approach\". While conventional pharmacology focuses on individual drug effects, it struggles with the complexities of polypharmacy, where multiple medications interact via shared metabolic pathways. This article highlights integrating systemic maps into educational methodologies to empower students in identifying and assessing medication risks. By visualizing the body and drug therapy as interconnected systems, students can better understand complex pharmacological interactions beyond linear frameworks. This approach enables active learning and real-life case analysis, such as cardiovascular prevention with non-selective antidepressants, where multiple drug interactions must be considered. It also fosters global health education by promoting the exchange of effective teaching practices and addressing challenges in healthcare training. Systemic maps prepare students for clinical decision-making by enhancing their ability to manage risks and complex cases effectively.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Historical Process, Status and Future Development of Pharmacovigilance Systems in Chinese Medicine. 中药药物警戒系统的历史进程、现状与未来发展。

IF 1.8

Pharmacy Pub Date : 2025-06-26 DOI: 10.3390/pharmacy13040090

Xue Wang, Yinfeng Wang, Xiaomeng Zhang, Bing Zhang, Zhijian Lin

引用次数: 0

Clinical Outcomes of Pharmacist Involvement in Cardiac Arrest and Trauma Resuscitations: A Scoping Review. 药剂师参与心脏骤停和创伤复苏的临床结果：一项范围审查。

IF 1.8

Pharmacy Pub Date : 2025-06-24 DOI: 10.3390/pharmacy13040089

Harshita Patel, Myles Wee, Aaron M Tejani, Anthony Lau

{"title":"Clinical Outcomes of Pharmacist Involvement in Cardiac Arrest and Trauma Resuscitations: A Scoping Review.","authors":"Harshita Patel, Myles Wee, Aaron M Tejani, Anthony Lau","doi":"10.3390/pharmacy13040089","DOIUrl":"10.3390/pharmacy13040089","url":null,"abstract":"Background: The role of clinical pharmacists in the emergency department continues to gain recognition, particularly during cardiac and trauma resuscitations. However, their contributions to patient outcomes remain unclear. The objective of this scoping review with narrative synthesis was to determine the impact of pharmacists on medication and patient outcomes during cardiac and trauma resuscitations and to identify barriers to integration.Methods: A literature search of databases in September 2024 identified randomized and non-randomized control trials, evaluating the impact of pharmacists' involvement in cardiac or trauma resuscitations. Excluded were studies on acute stroke, acute hemorrhage, and sepsis. Data were extracted and analyzed for primary (e.g., medication errors and Advanced Cardiovascular Life Support [ACLS] compliance) and secondary outcomes (e.g., pharmacists' education and training).Results: Of the 560 records screened, 26 records were included in the final analysis. Due to heterogeneity, quantitative analysis was not feasible. Among primary outcomes, ACLS guideline compliance and medication errors were commonly reported; mortality and length of stay were less commonly reported. ACLS certification improved pharmacists' confidence in their tasks. Pharmacists' presence also correlated with reduced healthcare costs.Conclusions: Our analysis suggests that the involvement of pharmacists in the context of emergency cardiac or trauma resuscitations may benefit direct patient outcomes and indirect outcomes.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacy最新文献